Sugi Predict

Sugi Predict / Compounds / SCHEMBL1896897

SCHEMBL1896897

SCHEMBL1896897

O=C(Oc1ccc2ccccc2c1)C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.56
▸ MEN1 O00255 4/20 0.56
▸ MAPT P10636 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ ALDH1A1 P00352 3/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ ESR1 P03372 2/20 0.48
▸ ESR2 Q92731 2/20 0.48
▸ PTPN7 P35236 1/20 0.47
▸ MMP1 P03956 2/20 0.46
▸ MMP12 P39900 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ FABP7 O15540 1/20 0.45
▸ FABP3 P05413 1/20 0.45
▸ BCHE P06276 1/20 0.45
▸ FAAH O00519 1/20 0.45
▸ EPHX1 P07099 1/20 0.45
▸ MMP2 P08253 1/20 0.45
▸ NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12128694 0.86 KMT2A (0.53) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL22767768 0.83 KMT2A (0.54) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL2605924 0.82 KMT2A (0.49) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL15114254 0.82 AGXT (0.50) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL30339521 0.81 ELANE (0.58) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL12618375 0.81 ELANE (0.58) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL985436 0.81 KMT2A (0.56) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL14035685 0.80 KMT2A (0.47) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL19042444 0.80 CA2 (0.50) KMT2AMEN1MAPTTDP1ALDH1A1
SCHEMBL14009328 0.80 KMT2A (0.47) KMT2AMEN1MAPTTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221700-A Condensed ring aromatic compound, preparation method and application thereof 北京华森英诺生物科技有限公司 2024-06-21 — — CN disclosed
CN-117327102-A KRAS inhibitor, preparation method and application thereof 北京华森英诺生物科技有限公司 2024-01-02 — — CN disclosed
CN-116731045-A KRAS inhibitor, preparation method and application thereof 北京华森英诺生物科技有限公司 2023-09-12 — — CN disclosed
CN-109843856-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2023-05-02 — — CN disclosed
WO-2023056951-A1 ARYL-SUBSTITUTED HETEROCYCLIC COMPOUND 杭州德睿智药科技有限公司 2023-04-13 — — WO disclosed
WO-2022068921-A1 QUINAZOLINE COMPOUND AND APPLICATION THEREOF 上海医药集团股份有限公司 2022-04-07 — — WO disclosed
CN-111989321-A KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2020-11-24 — — CN disclosed
CN-101300488-B Complex formation method and separation method WAKO PURE CHEMICAL INDUSTRY CO LTD 2012-09-05 — — CN disclosed
EP-1383793-B1 INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS DGI BIOTECHNOLOGIES L L C (US) 2011-10-19 — — EP disclosed
EP-2368902-A2 Insulin and IGF-1 receptor agonists and antagonists DGI Bio Technologies LLC (US) 2011-09-28 — — EP disclosed
US-20040023887-A1 Insulin and IGF-1 receptor agonists and antagonists NOVO NORDISK A/S (DK) 2004-02-05 — — US disclosed
WO-2004009086-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP ELI LILLY AND COMPANY (US) 2004-01-29 — — WO disclosed
EP-1383793-A2 INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS DGI BioTechnologies, L.L.C. (US) 2004-01-28 — — EP disclosed
US-20030236190-A1 Isulin and IGF-1 receptor agonists and antagonists ANTYRA, INC. 2003-12-25 — — US disclosed
US-20030195147-A1 Insulin and IGF-1 receptor agonists and antagonists NOVO NORDISK A/S (DK) 2003-10-16 — — US disclosed
WO-2003070747-A2 INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS NOVO NORDISK A/S (DK) 2003-08-28 — — WO disclosed
WO-2003027246-A2 ANTAGONISTS NOVO NORDISK A/S (DK) 2003-04-03 — — WO disclosed
US-6387879-B1 POLYPEPTIDES DGI BIOTECHNOLOGIES, INC. 2002-05-14 — — US disclosed
WO-2001072771-A2 INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS DGI BIOTECHNOLOGIES, L.L.C. (US) 2001-10-04 — — WO disclosed
CN-1149869-A Substituted sulfonamides as selective beta3 agonists for treatment of diabetes and obesity MERCK & CO LTD (US) 1997-05-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236190-A1 Isulin and IGF-1 receptor agonists and antagonists IGF1R, IGFBP1, IGFBP2 KMT2A 4722/4885MEN1 809/4885MAPT 4434/4885
US-20040023887-A1 Insulin and IGF-1 receptor agonists and antagonists IGF1R, IGFBP1, IGFBP2 KMT2A 4145/4885MEN1 754/4885MAPT 4451/4885
US-20030195147-A1 Insulin and IGF-1 receptor agonists and antagonists IGF1R, IGFBP1, IGFBP2 KMT2A 4162/4885MEN1 761/4885MAPT 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.